NAD+ and Aging: What the Studies Actually Show

NAD+ (nicotinamide adenine dinucleotide) is involved in hundreds of cellular reactions, and levels measurably decline with age — some estimates put the drop as high as 80% by later life. That decline, plus NAD+'s role in energy metabolism and DNA repair, is why NAD+ boosting became one of the most talked-about strategies in longevity circles. The human trial data is now substantial enough to say something more precise than "promising" — it's genuinely a mixed picture, and the mix matters. What the Human Trials Actually Show There are now more than a dozen human clinical trials on NAD+ precursors — primarily nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — running up to 26 weeks, with at least one extending to two years. Across that body of research, a few consistent findings have emerged. First, the safety data is solid: repeated dosing at gram-level amounts has been evaluated in randomized, placebo-controlled trials, and no major safety signals have emerged. Second, both NR and NMN reliably do the one thing they're designed to do — raise circulating NAD+ levels. A direct three-way comparison published in Nature Metabolism in 2026 found NR and NMN roughly doubled blood NAD+ after just 14 days, while plain nicotinamide (NAM) did not, despite being cheaper and more commonly found in over-the-counter B3 supplements. Where the picture gets more complicated is the third question: does raising blood NAD+ actually produce the functional, healthspan-level benefits people are hoping for? Here the evidence is thinner and more mixed. Some specific outcomes have shown real signal — one trial in prediabetic women found NMN improved muscle insulin sensitivity, and a separate trial in older adults with insomnia symptoms found meaningful improvements in sleep duration and quality. But broader functional measures — cardiovascular health markers, walking speed, and skeletal muscle NAD+ concentration specifically (as opposed to blood levels) — have not shown consistent improvement across trials. In fact, one notable NR trial found no improvement in walking speed in the treatment group, while the placebo group actually improved — a reminder that these trials are genuinely hard to design well, and modest effect sizes get easily lost in the noise. The honest summary from the current data: NAD+ precursors are a safe, well-studied way to reliably raise a specific blood biomarker. Whether that biomarker change reliably produces the broader anti-aging outcomes associated with NAD+ in animal models is still an open, actively researched question — not a settled one. Other Compounds in the Same Research Conversation NAD+ precursors aren't the only research interest in the cellular-energy and longevity space. A few other compounds come up frequently in the same conversations, though it's worth being clear that the human evidence behind them is generally much earlier-stage than what exists for NR and NMN: Epitalon is a synthetic peptide based on a naturally occurring pineal gland compound, studied primarily in earlier Russian research for its proposed effects on telomerase activity and circadian regulation. The human trial base here is far smaller and older than the NAD+ precursor literature, and much of the foundational work hasn't been replicated under modern trial standards. MOTS-c is a mitochondrial-derived peptide that has drawn research interest as a kind of "exercise mimetic" — animal studies suggest it influences metabolic regulation and insulin sensitivity through pathways that intersect with cellular energy production, which is conceptually adjacent to what NAD+ does. Human data remains limited and mostly early-stage. SS-31 (elamipretide) is a mitochondria-targeted peptide that has actually reached human clinical trials, primarily in the context of specific mitochondrial and cardiac conditions rather than general longevity use — it's a useful example of a compound whose research program is more mature, even though its studied population and use case are narrower than general aging. The mechanistic logic for grouping these with NAD+ research is real — they all touch different points in the same broader cellular energy and mitochondrial function system. But it's worth being precise that "mechanistically related" and "proven to work together" are very different claims, and the quality and quantity of human evidence varies enormously across this list. Layering multiple under-studied compounds together doesn't just add their individual uncertainties — it compounds them, since there's essentially no research on how they interact with each other in humans. The Bottom Line NAD+ precursor supplementation has a genuinely solid human safety record and a reliable ability to raise blood NAD+ levels — that part isn't in dispute. What remains unsettled is how much that translates into the broader healthspan benefits associated with NAD+ in preclinical models, with some specific outcomes (sleep, insulin sensitivity in certain populations) showing real promise and others (cardiovascular markers, physical performance) not yet showing consistent effects. The other peptides sometimes discussed alongside NAD+ research are mechanistically interesting but sit much earlier on the evidence curve — worth watching, not worth assuming.